RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
TOT BIOPHARM International Co Stock

TOT BIOPHARM International Co ROE 2024

TOT BIOPHARM International Co ROE

-0.05

Ticker

1875.HK

ISIN

HK0000545266

In 2024, TOT BIOPHARM International Co's return on equity (ROE) was -0.05, a -21.36% increase from the -0.07 ROE in the previous year.

TOT BIOPHARM International Co Aktienanalyse

What does TOT BIOPHARM International Co do?

TOT BIOPHARM International Co Ltd is a global biotechnology company based in Hong Kong. It was founded in 2005 and has since become a major player in the biopharmaceutical industry. The company's goal is to contribute to the improvement of medical care through innovative research and development of biological drugs. TOT BIOPHARM's business activities include pharmaceutical development, clinical research, and production of biological drugs. It serves various sectors, including cancer, immunology, ophthalmology, and vaccines. TOT BIOPHARM is strongly committed to the development of biopharmaceuticals and aims to be a leader in this field. One important focus of TOT BIOPHARM is the research of cancer drugs. The company has several drugs in its oncology pipeline, including a treatment for lung cancer called "Ponatinib". Additionally, TOT BIOPHARM has introduced a range of immuno-oncology therapies that can be used to treat various types of cancer. In the field of immunology, TOT BIOPHARM has launched several drugs for the treatment of autoimmune diseases, including "Natalizumab" for multiple sclerosis. Another important immunotherapy developed by TOT BIOPHARM is "Eculizumab," which is used to treat two rare blood disorders. In ophthalmology, TOT BIOPHARM is developing a new drug for the treatment of wet age-related macular degeneration (AMD). The drug is being tested in a Phase III clinical trial and has the potential to become the first biopharmaceutical for the treatment of AMD. Furthermore, TOT BIOPHARM has also developed vaccines, including a vaccine against the Japanese encephalitis virus (JEV) and a vaccine against enterovirus 71 (EV71). Both vaccines have been approved in China and are in high demand. TOT BIOPHARM's business model focuses on building a pipeline of innovative biopharmaceuticals that meet the needs of patients. The company operates a comprehensive research and development infrastructure that helps discover and develop new drug candidates. TOT BIOPHARM collaborates with universities, government agencies, and other business partners to accelerate its research and development and strengthen its market position. In addition, TOT BIOPHARM has a strong presence in the Chinese market for biopharmaceuticals. The company has a state-approved clinical research facility with over 1,000 employees in China and collaborates with leading Chinese hospitals and specialty clinics. This has given TOT BIOPHARM a preferred position in the Chinese market for biopharmaceuticals, and the company aims to expand its presence in other markets worldwide. Overall, TOT BIOPHARM International Co Ltd has built an impressive portfolio of biopharmaceuticals in recent years and is expected to continue to play a significant role in the biopharmaceutical industry. With a clear focus on research and development and a growing market position in China and other countries, the company is well-positioned to expand its business activities and strengthen its presence in the global market. TOT BIOPHARM International Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding TOT BIOPHARM International Co's Return on Equity (ROE)

TOT BIOPHARM International Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing TOT BIOPHARM International Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

TOT BIOPHARM International Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in TOT BIOPHARM International Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about TOT BIOPHARM International Co stock

What is the ROE (Return on Equity) of TOT BIOPHARM International Co this year?

The ROE of TOT BIOPHARM International Co this year is -0.05 undefined.

How has the Return on Equity (ROE) of TOT BIOPHARM International Co developed compared to the previous year?

The ROE of TOT BIOPHARM International Co has increased by -21.36% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of TOT BIOPHARM International Co?

A high ROE indicates that TOT BIOPHARM International Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of TOT BIOPHARM International Co?

A low ROE can indicate that TOT BIOPHARM International Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of TOT BIOPHARM International Co affect the company?

A change in ROE (Return on Equity) of TOT BIOPHARM International Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of TOT BIOPHARM International Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of TOT BIOPHARM International Co?

Some factors that can influence TOT BIOPHARM International Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does TOT BIOPHARM International Co pay?

Over the past 12 months, TOT BIOPHARM International Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TOT BIOPHARM International Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of TOT BIOPHARM International Co?

The current dividend yield of TOT BIOPHARM International Co is .

When does TOT BIOPHARM International Co pay dividends?

TOT BIOPHARM International Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TOT BIOPHARM International Co?

TOT BIOPHARM International Co paid dividends every year for the past 0 years.

What is the dividend of TOT BIOPHARM International Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is TOT BIOPHARM International Co located?

TOT BIOPHARM International Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von TOT BIOPHARM International Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TOT BIOPHARM International Co from 10/2/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did TOT BIOPHARM International Co pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of TOT BIOPHARM International Co in the year 2023?

In the year 2023, TOT BIOPHARM International Co distributed 0 CNY as dividends.

In which currency does TOT BIOPHARM International Co pay out the dividend?

The dividends of TOT BIOPHARM International Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von TOT BIOPHARM International Co

Our stock analysis for TOT BIOPHARM International Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TOT BIOPHARM International Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.